[go: up one dir, main page]

WO2023137500A3 - Cannabidiol and beta-caryophyllene in combination with condensed tannins and c-ring isomerized condensed tannins (phlobatannins) compositions to treat gynecological diseases and disorders - Google Patents

Cannabidiol and beta-caryophyllene in combination with condensed tannins and c-ring isomerized condensed tannins (phlobatannins) compositions to treat gynecological diseases and disorders Download PDF

Info

Publication number
WO2023137500A3
WO2023137500A3 PCT/US2023/060780 US2023060780W WO2023137500A3 WO 2023137500 A3 WO2023137500 A3 WO 2023137500A3 US 2023060780 W US2023060780 W US 2023060780W WO 2023137500 A3 WO2023137500 A3 WO 2023137500A3
Authority
WO
WIPO (PCT)
Prior art keywords
condensed tannins
phlobatannins
caryophyllene
cannabidiol
isomerized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/060780
Other languages
French (fr)
Other versions
WO2023137500A2 (en
Inventor
Tami Ehrmann BARR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Companion Sciences LLC
Original Assignee
Companion Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Companion Sciences LLC filed Critical Companion Sciences LLC
Publication of WO2023137500A2 publication Critical patent/WO2023137500A2/en
Publication of WO2023137500A3 publication Critical patent/WO2023137500A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Embodiments of the invention are directed to formulations comprising at least one of cannabidiol (CBD) and beta-caryophyllene and at least one of condensed tannins and C- ring isomerized condensed tannins (phlobatannins). Further embodiments of the invention are directed to methods of treating or preventing gynecological disease, conditions, disorders and symptoms, including inter alia menstrual pain and discomfort, wherein the method comprises administering a formulation comprising at least one of cannabidiol (CBD) and beta-caryophyllene and at least one of condensed tannins and C- ring isomerized condensed tannins (phlobatannins).
PCT/US2023/060780 2022-01-14 2023-01-17 Cannabidiol and beta-caryophyllene in combination with condensed tannins and c-ring isomerized condensed tannins (phlobatannins) compositions to treat gynecological diseases and disorders Ceased WO2023137500A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263299497P 2022-01-14 2022-01-14
US63/299,497 2022-01-14

Publications (2)

Publication Number Publication Date
WO2023137500A2 WO2023137500A2 (en) 2023-07-20
WO2023137500A3 true WO2023137500A3 (en) 2023-09-14

Family

ID=87279817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060780 Ceased WO2023137500A2 (en) 2022-01-14 2023-01-17 Cannabidiol and beta-caryophyllene in combination with condensed tannins and c-ring isomerized condensed tannins (phlobatannins) compositions to treat gynecological diseases and disorders

Country Status (1)

Country Link
WO (1) WO2023137500A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190177674A1 (en) * 2017-12-11 2019-06-13 CBD Spirits, LLC Systems, methods, and compositions of blended cannabinoid enriched beverages
US20190231826A1 (en) * 2015-07-22 2019-08-01 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US20210274814A1 (en) * 2019-07-03 2021-09-09 Vertosa, Inc. Infusion of emulsified hydrophobic active ingredients into high polyphenolic beverages
US20210299086A1 (en) * 2015-02-27 2021-09-30 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210299086A1 (en) * 2015-02-27 2021-09-30 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20190231826A1 (en) * 2015-07-22 2019-08-01 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US20190177674A1 (en) * 2017-12-11 2019-06-13 CBD Spirits, LLC Systems, methods, and compositions of blended cannabinoid enriched beverages
US20210274814A1 (en) * 2019-07-03 2021-09-09 Vertosa, Inc. Infusion of emulsified hydrophobic active ingredients into high polyphenolic beverages

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PREMIER STAFF: "Demystifying Wine Tannins", WINE DEALS - BLOG, pages 1 - 2, XP009549713, Retrieved from the Internet <URL:https://www.winedeals.com/blog/post/what-are-tannins-in-wine-and-how-they-affect-you> *

Also Published As

Publication number Publication date
WO2023137500A2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
US5455033A (en) Medicinal composition for treatment of inflammation
KECZKES et al. Do corticosteroids prevent post‐herpetic neuralgia?
US20190054062A1 (en) Topical Compositions for Treatment of Psoriasis
EP2278986B1 (en) A product for topical administration
Inanmdar et al. Clinical efficacy of Trigonella foenum graecum (Fenugreek) and dry cupping therapy on intensity of pain in patients with primary dysmenorrhea
US20130108599A1 (en) Herbal Vaginal Compositions
JP5540474B2 (en) Nerve elongation inhibitor
US7879372B2 (en) Method and composition for treating ear inflammation caused by dry ear
JP2018519361A (en) Formulations for the treatment of oral, throat and airway disorders
Kucera et al. Effects of Symphytum ointment on muscular symptoms and functional locomotor disturbances
WO2023137500A3 (en) Cannabidiol and beta-caryophyllene in combination with condensed tannins and c-ring isomerized condensed tannins (phlobatannins) compositions to treat gynecological diseases and disorders
JP2000512270A (en) Compositions and methods for the treatment of herpes simplex
US11590211B2 (en) Systems for treating dermal inflammatory conditions
EP3294267A1 (en) Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity
WO2019142124A4 (en) Pharmaceutical compositions for treatment of vitiligo
US20130243702A1 (en) Mouthwash Composition for Managing Oral Mucositis, Process and Methods Thereof
CN106822321B (en) Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris
CN109091584A (en) A kind of swelling and pain relieving ointment and preparation method thereof
CN109276594A (en) A kind of traditional Chinese medicine composition for treating snake string sore and preparation method thereof
GB2293547A (en) Compositions containing tea tree oil
US20060088612A1 (en) Composition for treatment of topical infection and methods of making and using same
EP1900372B1 (en) Composition for enhancing male fertility
MX2023005663A (en) RESPIRATORY TREATMENTS.
CN105770656A (en) Traditional Chinese medicine powder for treating skin pruritus and application thereof
Lestringant et al. Effectiveness of amorolfine 5% nail lacquer in the treatment of long-duration Candida onychomycosis with chronic paronychia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23740913

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23740913

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC